ProCE Banner Activity

Premium Education

Integrating Oral SERDs Into Treatment for Patients With HR-positive/HER2-negative Metastatic Breast Cancer and Current Rationale or Medical Need

Slideset

Download these slides from a live satellite symposium at the San Antonio Breast Cancer Symposium covering strategies for integrating oral SERDs into the management of patients with HR-positive/HER2-negative metastatic breast cancer.

Released: November 13, 2024

Expiration: November 12, 2025

Course Fee

$100.00

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Lilly

AstraZeneca

Lilly